TMDX
TransMedics Group, Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
95.00
▲ 4.15 (4.57%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
91.25
Prev close
90.85
Day high
95.18
Day low
90.45
Volume
621.55K
Market cap
—
P/E (TTM)
—
52W range
60.11 – 156.00
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+6.99%
+8.4%
1M
+33.23%
+29.5%
3M
+37.65%
+34.6%
6M
-29.41%
-40.5%
YTD
-22.10%
-34.4%
1Y
-22.24%
-42.2%
3Y
+49.36%
-24.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $605.49M | $441.54M | $241.62M | $93.46M | +37.1% |
| Operating revenue | $605.49M | $441.35M | $241.60M | $92.08M | +37.2% |
| Cost of revenue | $242.69M | $179.46M | $87.53M | $28.19M | +35.2% |
| Gross profit | $362.81M | $262.08M | $154.09M | $65.27M | +38.4% |
| Research & development | $69.06M | $55.97M | $63.27M | $26.81M | +23.4% |
| Selling, general & admin | $185.17M | $168.62M | $119.55M | $69.90M | +9.8% |
| Total operating expense | $254.22M | $224.59M | $182.82M | $96.71M | +13.2% |
| Operating income | $108.58M | $37.50M | -$28.73M | -$31.44M | +189.6% |
| Net interest income | -$13.78M | -$14.41M | -$10.79M | -$3.73M | +4.4% |
| Pre-tax income | $107.52M | $35.78M | -$26.67M | -$36.16M | +200.5% |
| Tax provision | -$82.77M | $316.00K | -$1.64M | $66.00K | -26,292.7% |
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | +436.6% |
| Net income to common | $190.29M | $35.46M | -$25.03M | -$36.23M | +436.6% |
| Basic EPS | 5.60 | 1.07 | -0.77 | -1.23 | +423.4% |
| Diluted EPS | 4.87 | 1.01 | -0.77 | -1.23 | +382.2% |
| EBIT | $121.30M | $50.19M | -$15.88M | -$32.44M | +141.7% |
| EBITDA | $148.49M | $69.95M | -$7.70M | -$28.96M | +112.3% |
| Basic shares | 33.99M | 33.23M | 32.52M | 29.56M | +2.3% |
| Diluted shares | 40.54M | 35.22M | 32.52M | 29.56M | +15.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $488.37M | $336.65M | $394.81M | $201.18M | +45.1% |
| Cash & short-term investments | $488.37M | $336.65M | $394.81M | $201.18M | +45.1% |
| Accounts receivable | $84.28M | $97.72M | $63.58M | $27.61M | -13.8% |
| Inventory | $48.88M | $46.55M | $44.23M | $20.61M | +5.0% |
| Total current assets | $637.78M | $497.22M | $510.65M | $252.29M | +28.3% |
| Property, plant & equipment | $332.81M | $292.45M | $180.49M | $24.35M | +13.8% |
| Goodwill & intangibles | $13.50M | $13.70M | $14.34M | $0 | -1.5% |
| Total assets | $1.07B | $804.08M | $706.05M | $277.15M | +32.9% |
| Total current liabilities | $89.31M | $59.91M | $54.93M | $23.66M | +49.1% |
| Current debt | $10.00M | — | — | — | — |
| Long-term debt | $502.39M | $509.31M | $506.20M | $58.70M | -1.4% |
| Total debt | $519.28M | $518.29M | $515.95M | $67.56M | +0.2% |
| Total liabilities | $595.27M | $575.47M | $568.85M | $89.77M | +3.4% |
| Retained earnings | -$277.95M | -$468.24M | -$503.70M | -$478.68M | +40.6% |
| Shareholder equity | $473.10M | $228.60M | $137.20M | $187.38M | +107.0% |
| Working capital | $548.48M | $437.30M | $455.72M | $228.63M | +25.4% |
| Net tangible assets | $459.60M | $214.90M | $122.86M | $187.38M | +113.9% |
| Shares issued | 34.27M | 33.62M | 32.67M | 32.14M | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | +436.6% |
| Depreciation & amortisation | $27.18M | $19.76M | $8.18M | $3.48M | +37.6% |
| Stock-based compensation | $36.86M | $33.22M | $19.79M | $10.32M | +10.9% |
| Change in working capital | $18.38M | -$45.00M | -$44.35M | -$26.76M | +140.8% |
| Operating cash flow | $192.84M | $48.80M | -$13.03M | -$45.82M | +295.1% |
| Capital expenditure | -$59.25M | -$129.74M | -$179.06M | -$11.91M | +54.3% |
| Investing cash flow | -$59.25M | -$129.30M | -$193.95M | $54.51M | +54.2% |
| Financing cash flow | $16.86M | $22.87M | $400.42M | $167.93M | -26.3% |
| Free cash flow | $133.59M | -$80.94M | -$192.09M | -$57.72M | +265.0% |
| End cash position | $488.87M | $337.15M | $395.31M | $201.68M | +45.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $189.95M | $173.93M | $160.76M | $143.82M | $157.37M | +9.2% |
| Operating revenue | $189.95M | $173.93M | $160.76M | $143.82M | $157.37M | +9.2% |
| Cost of revenue | $76.75M | $72.77M | $67.35M | $59.25M | $60.78M | +5.5% |
| Gross profit | $113.20M | $101.16M | $93.41M | $84.58M | $96.59M | +11.9% |
| Research & development | $31.63M | $24.88M | $20.70M | $15.26M | $15.93M | +27.1% |
| Selling, general & admin | $53.54M | $56.92M | $51.44M | $46.02M | $42.44M | -5.9% |
| Total operating expense | $89.46M | $87.86M | $72.14M | $61.27M | $60.02M | +1.8% |
| Operating income | $23.74M | $13.30M | $21.27M | $23.30M | $36.57M | +78.5% |
| Net interest income | -$4.22M | -$7.17M | -$11.45M | -$191.00K | -$976.00K | +41.1% |
| Pre-tax income | $19.41M | $8.48M | $21.63M | $23.03M | $36.18M | +128.7% |
| Tax provision | $4.72M | $1.17M | -$83.75M | -$1.29M | $1.27M | +303.7% |
| Net income | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | +100.7% |
| Net income to common | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | +100.7% |
| Basic EPS | 0.42 | 0.21 | 3.08 | 0.71 | 1.03 | +100.0% |
| Diluted EPS | 0.41 | 0.20 | 2.62 | 0.66 | 0.92 | +105.0% |
| EBIT | $26.63M | $15.65M | $24.99M | $26.52M | $39.66M | +70.1% |
| EBITDA | $36.87M | $27.52M | $32.45M | $33.37M | $46.39M | +34.0% |
| Basic shares | 34.58M | 34.38M | 34.22M | 34.11M | 33.91M | +0.6% |
| Diluted shares | 40.71M | 36.19M | 40.93M | 40.75M | 40.56M | +12.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $472.68M | $461.74M | $488.37M | $466.17M | $400.57M | +2.4% |
| Cash & short-term investments | $472.68M | $461.74M | $488.37M | $466.17M | $400.57M | +2.4% |
| Accounts receivable | $104.14M | $90.73M | $84.28M | $80.70M | $104.85M | +14.8% |
| Inventory | $54.14M | $49.89M | $48.88M | $44.51M | $38.87M | +8.5% |
| Total current assets | $651.12M | $619.28M | $637.78M | $613.00M | $558.13M | +5.1% |
| Property, plant & equipment | $702.42M | $700.97M | $332.81M | $318.76M | $318.07M | +0.2% |
| Goodwill & intangibles | $11.55M | $11.55M | $13.50M | $13.55M | $13.60M | 0.0% |
| Total assets | $1.46B | $1.43B | $1.07B | $946.03M | $890.52M | +2.1% |
| Total current liabilities | $98.28M | $91.92M | $89.31M | $79.72M | $56.62M | +6.9% |
| Current debt | $20.00M | $15.00M | $10.00M | $5.00M | — | +33.3% |
| Long-term debt | $494.00M | $498.19M | $502.39M | $506.69M | $510.89M | -0.8% |
| Total debt | $867.72M | $863.41M | $519.28M | $519.35M | $518.82M | +0.5% |
| Total liabilities | $946.34M | $940.81M | $595.27M | $590.83M | $572.42M | +0.6% |
| Retained earnings | -$255.95M | -$270.63M | -$277.95M | -$383.33M | -$407.65M | +5.4% |
| Shareholder equity | $518.05M | $494.01M | $473.10M | $355.20M | $318.10M | +4.9% |
| Working capital | $552.84M | $527.36M | $548.48M | $533.27M | $501.51M | +4.8% |
| Net tangible assets | $506.50M | $482.46M | $459.60M | $341.65M | $304.50M | +5.0% |
| Shares issued | 34.63M | 34.55M | 34.27M | 34.14M | 34.04M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $14.68M | $7.32M | $105.38M | $24.32M | $34.91M | +100.7% |
| Depreciation & amortisation | $10.24M | $11.86M | $7.47M | $6.85M | $6.73M | -13.7% |
| Stock-based compensation | $8.61M | $9.95M | $9.39M | $9.14M | $9.37M | -13.5% |
| Change in working capital | -$25.44M | -$11.35M | -$5.34M | $27.93M | $40.19M | -124.1% |
| Operating cash flow | $17.31M | $24.53M | $34.51M | $69.57M | $91.61M | -29.4% |
| Capital expenditure | -$7.09M | -$36.66M | -$15.51M | -$7.62M | -$9.07M | +80.7% |
| Investing cash flow | -$7.09M | -$36.66M | -$15.51M | -$7.62M | -$9.07M | +80.7% |
| Financing cash flow | $970.00K | $3.76M | $3.10M | $3.64M | $7.09M | -74.2% |
| Free cash flow | $10.22M | -$12.12M | $19.00M | $61.95M | $82.53M | +184.3% |
| End cash position | $491.11M | $480.18M | $488.87M | $466.67M | $401.07M | +2.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
90.16
+5.36% from price
SMA 20
84.29
+12.44% from price
SMA 50
77.47
+22.34% from price
SMA 100
82.64
+14.95% from price
SMA 200
106.31
-10.85% from price
EMA 12
88.65
+7.16% from price
EMA 26
83.90
+13.23% from price
EMA 50
81.59
+16.44% from price
RSI (14)
68.1
Neutral
MACD (12,26,9)
4.75
Hist 0.83
ATR (14)
4.63
4.89% of price
Realised vol 30D
48.4%
Annualised
Bollinger upper
97.17
20, 2σ
Bollinger lower
71.40
20, 2σ
50 / 200 cross
Death
77.47 vs 106.31
Trend bias
Below 200
-10.85%
Risk profile
Beta vs SPY
1.18
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
48.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-58.8%
Peak to trough
Max drawdown 5Y
-67.8%
Peak to trough
ATR 14
4.63
4.89% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
MarketBeat · 5d ago
TransMedics (TMDX) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
Zacks · 17d ago
Why TransMedics Stock Is Sinking Today
Motley Fool · 17d ago
UBS Adjusts Price Target on TransMedics Group to $77 From $80, Maintains Neutral Rating
MT Newswires · 18d ago
TransMedics Group (TMDX) Stock Looks Cheap On Earnings But Full After 171% Gain
Simply Wall St. · 18d ago
TransMedics Group Inc (TMDX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...
GuruFocus.com · 18d ago
TransMedics Group Q2 Earnings Call Highlights
MarketBeat · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.